DK2101805T3 - Integrinligander til anvendelse i behandling af cancer - Google Patents

Integrinligander til anvendelse i behandling af cancer

Info

Publication number
DK2101805T3
DK2101805T3 DK08707093.4T DK08707093T DK2101805T3 DK 2101805 T3 DK2101805 T3 DK 2101805T3 DK 08707093 T DK08707093 T DK 08707093T DK 2101805 T3 DK2101805 T3 DK 2101805T3
Authority
DK
Denmark
Prior art keywords
integric
lands
cancer treatment
cancer
treatment
Prior art date
Application number
DK08707093.4T
Other languages
English (en)
Inventor
Michael Weller
Ulrike Grimm
Simon Goodman
Andreas Harstrick
Stefan Krueger
Martin Andreas Picard
Johannes Nippgen
Roger Stupp
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/001446 external-priority patent/WO2007084670A2/en
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK2101805T3 publication Critical patent/DK2101805T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK08707093.4T 2007-01-18 2008-01-17 Integrinligander til anvendelse i behandling af cancer DK2101805T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2007/001446 WO2007084670A2 (en) 2006-01-18 2007-01-18 Specific therapy using integrin ligands for treating cancer
EP07014070 2007-07-18
PCT/EP2008/000328 WO2008087025A2 (en) 2007-01-18 2008-01-17 Specific therapy and medicament using integrin ligands for treating cancer

Publications (1)

Publication Number Publication Date
DK2101805T3 true DK2101805T3 (da) 2013-01-21

Family

ID=39402737

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08707093.4T DK2101805T3 (da) 2007-01-18 2008-01-17 Integrinligander til anvendelse i behandling af cancer

Country Status (19)

Country Link
US (2) US20100069302A1 (da)
EP (4) EP2441464B1 (da)
JP (3) JP2010516645A (da)
KR (2) KR20090108713A (da)
CN (2) CN101588812A (da)
AU (2) AU2008207095B2 (da)
BR (2) BRPI0806596A2 (da)
CA (2) CA2675813A1 (da)
CO (1) CO6382135A2 (da)
DK (1) DK2101805T3 (da)
EA (2) EA017864B1 (da)
EC (1) ECSP109969A (da)
ES (2) ES2399159T3 (da)
IL (1) IL199696A0 (da)
MX (1) MX2009007597A (da)
PL (1) PL2101805T3 (da)
PT (1) PT2101805E (da)
WO (2) WO2008087025A2 (da)
ZA (1) ZA200905703B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101805T3 (da) * 2007-01-18 2013-01-21 Merck Patent Gmbh Integrinligander til anvendelse i behandling af cancer
CN102223915A (zh) * 2008-11-20 2011-10-19 默克专利有限公司 应用整联蛋白配体治疗癌症的新疗法和药物
CA2763275A1 (en) * 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
CA2775601C (en) 2009-09-28 2017-10-03 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
WO2011146819A2 (en) * 2010-05-20 2011-11-24 Dmd Therapies, Llc METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES
US20150309012A1 (en) * 2012-12-07 2015-10-29 Baxter International Inc. Anti-mif antibody cell migration assay
US20160317531A1 (en) * 2013-06-21 2016-11-03 The General Hospital Corporation Ribonucleotide reductase inhibitors sensitize tumor cells to dna damaging agents
KR101579054B1 (ko) * 2014-03-26 2015-12-21 한국원자력의학원 포도필로톡신 아세테이트를 유효 성분으로 포함하는 방사선치료 증진제
WO2016041616A1 (en) * 2014-09-17 2016-03-24 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
AU2015340359B2 (en) * 2014-10-30 2019-11-21 Big Dna Ltd Combination therapy
EP3207937A1 (en) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland A method of treating or preventing sepsis
CN105906692A (zh) * 2016-03-11 2016-08-31 李书鹏 cRGD-厄洛替尼缀合物及其制备方法
GB2554333A (en) * 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
US20200271654A1 (en) * 2017-02-06 2020-08-27 Expression Pathology, Inc. Quantifying MGMT Protein For Optimal Cancer Therapy
US20240082347A1 (en) 2021-01-22 2024-03-14 Royal College Of Surgeons In Ireland Treatment of coronavirus

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701446A (en) 1901-12-30 1902-06-03 Lewis W Wooten Cotton-chopper.
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
ATE175118T1 (de) 1990-10-05 1999-01-15 Medarex Inc Gezielte immunostimulierung mit bispezifischen stoffen
CA2097060A1 (en) 1990-12-04 1992-06-05 Peter J. Curtis Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
WO1995032710A1 (en) 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
CZ382496A3 (en) 1994-06-29 1997-12-17 Smithkline Beecham Corp Compounds representing antagonists of vitronectin receptors, process of their preparation, intermediates of such process, pharmaceutical composition containing the compounds and their use
JPH10504807A (ja) 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
IT1271688B (it) 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
ES2152412T3 (es) * 1994-08-08 2001-02-01 Debiopharm Sa Preparacion farmaceuticamente estable de oxaliplatino.
JPH10504825A (ja) 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
ES2197950T3 (es) 1995-06-29 2004-01-16 Smithkline Beecham Corporation Antagonistas del receptor de la integrina.
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
IL125033A0 (en) 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
TR199801255T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r antagonistleri.
PL327626A1 (en) 1995-12-29 1998-12-21 Smithkline Beecham Corp Antagonists of vitronectin receptor
SI9720021A (sl) 1996-03-20 1999-04-30 Hoechst Marion Roussel Triciklične spojine s specifično aktivnostjo za integrine, zlasti za integrine alfavbeta3, postopki za njihovo pripravo in intermediati teh postopkov, njihova aplikacija kot zdravila in farmacevtski sestavki, ki jih vsebujejo
JP2000508319A (ja) 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αｖβ３拮抗薬
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
WO1997041844A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
BR9709514A (pt) * 1996-05-31 1999-08-10 Scripps Research Inst Processo e composições úteis para a inibição de angiogénese mediada por alfa beta
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
CA2263999A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
JP2001501951A (ja) 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
AU717283B2 (en) 1996-10-30 2000-03-23 Merck & Co., Inc. Integrin antagonists
JP2001503060A (ja) 1996-10-30 2001-03-06 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
AU5596298A (en) 1996-12-09 1998-07-03 Cor Therapeutics, Inc. Integrin antagonists
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
EP1007026A4 (en) 1997-01-17 2002-08-07 Merck & Co Inc INTEGRIN ANTAGONISTS
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
WO1999005107A1 (en) 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
WO1999006049A1 (en) 1997-08-04 1999-02-11 Smithkline Beecham Corporation Integrin receptor antagonists
EP1027337A4 (en) 1997-09-04 2002-04-03 Smithkline Beecham Corp Integrin receptor Antagonist
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
IL135188A0 (en) 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
IL135189A0 (en) 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
FR2768734B1 (fr) 1997-09-24 2000-01-28 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
CA2315232A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
GEP20032921B (en) 1997-12-17 2003-03-25 Merck & Co Inc Integrin Receptor Antagonists Pharmaceutical Compositions Containing the Same and Methods for Treatment
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
HUP0100178A3 (en) 1997-12-17 2002-12-28 Merck & Co Inc Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
BR9907218A (pt) 1998-01-23 2000-10-24 Merck Patent Gmbh Anticorpo monoclonal anti alfav-integrina e seu uso para inibir a fixação de alfav-beta6-integrina à fibronectina
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038665A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2373937A1 (en) 1999-06-02 2000-12-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2001090384A1 (en) * 2000-05-19 2001-11-29 The Board Of Trustees Of The Leland Stanford Junior University Viral vectors useful in induction of humoral or cellular immunity
AU2001296511A1 (en) 2000-09-29 2002-04-08 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
JP4364510B2 (ja) * 2001-01-09 2009-11-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 受容体型チロシンキナーゼ阻害剤および血管新生阻害剤を用いる併用療法
PT1381384E (pt) * 2001-04-24 2011-09-01 Merck Patent Gmbh Terapia de combinação usando agentes anti-angiogénicos e tnfa
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
BRPI0706540A2 (pt) * 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
DK2101805T3 (da) * 2007-01-18 2013-01-21 Merck Patent Gmbh Integrinligander til anvendelse i behandling af cancer

Also Published As

Publication number Publication date
KR20090108713A (ko) 2009-10-16
PL2101805T3 (pl) 2013-04-30
JP2010533665A (ja) 2010-10-28
AU2008207095B2 (en) 2013-08-29
WO2008087025A2 (en) 2008-07-24
EP2164506A2 (en) 2010-03-24
EA200900912A1 (ru) 2009-12-30
CN101588812A (zh) 2009-11-25
EP2441464B1 (en) 2014-04-09
MX2009007597A (es) 2009-07-22
EP2441464A1 (en) 2012-04-18
JP2014015482A (ja) 2014-01-30
US20100190957A1 (en) 2010-07-29
PT2101805E (pt) 2013-01-31
EA017864B1 (ru) 2013-03-29
BRPI0806596A2 (pt) 2013-07-23
AU2008277904A1 (en) 2009-01-22
ES2399159T3 (es) 2013-03-26
ES2472450T3 (es) 2014-07-01
WO2008087025A3 (en) 2008-12-11
EP2101805B1 (en) 2012-11-07
ECSP109969A (es) 2010-03-31
AU2008207095A1 (en) 2008-07-24
EP2578225A1 (en) 2013-04-10
EA201000127A1 (ru) 2010-10-29
CA2675813A1 (en) 2008-07-24
IL199696A0 (en) 2010-04-15
WO2009010287A3 (en) 2009-04-09
JP2010516645A (ja) 2010-05-20
ZA200905703B (en) 2010-05-26
WO2009010287A2 (en) 2009-01-22
KR20100043242A (ko) 2010-04-28
EP2101805A2 (en) 2009-09-23
BRPI0813513A2 (pt) 2015-01-06
CN101743013A (zh) 2010-06-16
US20100069302A1 (en) 2010-03-18
CA2693862A1 (en) 2009-01-22
CO6382135A2 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DK2061561T3 (da) Sammensætninger til behandling af cancer
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
DK2205257T3 (da) Doseringsforskrifter for LAG-3Ig (IMP321) til anvendelse ved behandling af cancer
DK2127652T3 (da) Fremgangsmåde til behandling af cancer under anvendelse af anticancermiddel i kombination
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
DK2365802T3 (da) Mikrokapsler af rapamycin og anvendelse til behandling af cancer
BRPI0810206A2 (pt) Método de tratar câncer
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2121139T3 (da) Formulations for cancer treatment
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK2175851T3 (da) Biofilmbehandling
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2473510T3 (da) Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
BRPI0813670A2 (pt) Compostos para tratamento
DK2173831T3 (da) Brøndbehandling
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
DK2147122T3 (da) Enzymatisk kræftbehandling
DK2131841T3 (da) Fremgangsmåder til behandling af akut smerte
BRPI0818598A2 (pt) agentes terapêuticos - 802
DK2215314T3 (da) Indretning til behandling af regnvand
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer